We are advancing a pipeline of therapeutics focused on severe hematologic diseases. Led by ATV-1601 for hereditary hemorrhagic telangiectasia (HHT), our programs are designed to address significant unmet patient needs through innovative therapeutic approaches. Our AMPS™ platform enables the discovery of differentiated therapies for high-value targets, with an internal focus on severe hematologic diseases.
|
|
|
|
|
|
|
|
|
|
Hereditary Hemorrhagic Telangiectasia (HHT) is a severe, multi-organ disease with significant morbidity and mortality driven by epistaxis, anemia, and complications of visceral AVMs. It is the second most common inherited bleeding disorder, affecting more than 80,000 people in the US and 1.6 million people globally, with no approved therapies currently available.
For patients, their day to day is encumbered by chronic bleeding that limits their quality of life and independence. It also means they are more likely to need surgical or ablative interventions to help control bleeding and many also require blood transfusions and iron infusions to address the anemia. Management of the disease and complications requires a multidisciplinary team which adds a significant burden to patients over the course of their lifetime.
HHT is a genetically inherited disease caused by loss-of-function mutations in ENG, ALK1 and SMAD4 resulting in malformed blood vessels that can affect multiple organ systems throughout the body including the liver, lungs, gastrointestinal tract, and brain. Hyperactivation of the AKT1 pathway is a hallmark of the disease which results in the formation of abnormal blood vessels (AVMs) that rupture or cause abnormal blood flow and lead to chronic bleeding, anemia, organ damage, and for some, life-threatening complications.
Selectively inhibiting AKT1, the primary AKT isoform and driver of abnormal endothelial growth implicated in HHT, offers a novel and potentially disease-modifying therapeutic approach for this chronic bleeding disorder complicated by multiorgan involvement.
ATV-1601 is an investigational oral AKT1 selective inhibitor with the potential to deliver disease modifying efficacy for patients across all genetic subtypes of HHT.
This is a Phase 1/2 study evaluating the safety and efficacy of ATV-1601 and determining if it can help improve symptoms and potentially impact the underlying disease for individuals with moderate to severe Hereditary Hemorrhagic Telangiectasia (HHT).
For patients or caregivers to learn more about the study, please visit our trial site Harmony-HHT Study
Study sites are currently enrolling patients.
Please contact StudyDirector@atavistikbio.com for more information
Myeloproliferative neoplasms (MPNs) are a group of chronic blood cancers characterized by the overproduction of mature blood cells in the bone marrow, leading to significant morbidity and mortality driven by thrombotic events, bleeding complications, progressive marrow dysfunction, and risk of transformation into acute myeloid leukemia. The major subtypes – polycythemia vera, essential thrombocythemia, and myelofibrosis – collectively affect more than 300,000 people in the US.
The JAK2V617F mutation is the most common driver mutation in patients living with MPNs, affecting approximately 95% of patients with polycythemia vera (PV), 60% of patients with essential thrombocythemia (ET) and 55% of patients with myelofibrosis (MF). Selectively targeting JAK2V617F has the potential to reduce mutant allele burden, preserve normal bone marrow function, and have a disease modifying impact that could substantially improve long term outcomes and quality of life for patients with MPNs.
